Therapeutic area
Immunology and inflammation
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
30
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
139
Industry-sponsored
Recruiting Phase 3
90
Industry-sponsored
Recruiting Phase 4 (post-approval)
15
Industry-sponsored
Recent approvals
- Jakafi Xr (Ruxolitinib Phosphate) · Incyte Corp OrphanMay 1, 2026
- Icotyde (Icotrokinra Hydrochloride) · Janssen Biotech NovelPriority reviewMar 17, 2026
To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy
- Adquey (Difamilast) · Acrotech Biopharma NovelFeb 12, 2026
To treat mild to moderate atopic dermatitis
- Avtozma (Tocilizumab-Anoh) · Celltrion INC Jan 21, 2026
- Rhapsido (Remibrutinib) · Novartis NovelPriority reviewSep 30, 2025
To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment
- Anzupgo (Delgocitinib) · Leo Pharma As NovelJul 23, 2025
To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response
- Starjemza (Ustekinumab-Hmny) · Bio-Thera Solutions LTD May 22, 2025
- Steqeyma (Ustekinumab-Stba) · Celltrion, Inc. Apr 30, 2025
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025
- Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USA Apr 30, 2025
- Tyenne (Tocilizumab-Aazg) · Fresenius Kabi USA Mar 14, 2025
- Avtozma (Tocilizumab-Anoh) · Celltrion INC Jan 24, 2025
- Steqeyma (Ustekinumab-Stba) · Celltrion, Inc. Dec 17, 2024
- Dupixent (Dupilumab) · Regeneron Pharmaceuticals Breakthrough therapyPriority reviewSep 27, 2024
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- SHR-1819Phase 38 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Largest recruiting Phase 3 trials
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07116967 · 3,040 participants (planned) · Start Sep 22, 2025 · Primary completion Jan 16, 2031
Drug: Deucravacitinib; Ustekinumab · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 411 sites in all
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06651281 · 1,380 participants (planned) · Start Nov 25, 2024 · Primary completion Dec 17, 2037
Drug: Tulisokibart; Placebo to tulisokibart · For: Crohn Disease; Colitis, Ulcerative
Sites: Bristol, Connecticut; Ypsilanti, Michigan; Liberty, Missouri · 37 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07783425 · 1,375 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 8, 2028
Drug: Tilrekimig; Dupilumab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 50 sites in all
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06430801 · 1,200 participants (planned) · Start Jun 5, 2024 · Primary completion Oct 30, 2028
Drug: IV Tulisokibart; SC Tulisokibart · For: Crohn's Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 499 sites in all
- Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07286058 · 1,182 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 18, 2029
Drug: Zasocitinib · For: Psoriatic Arthritis
Sites: Tucson, Arizona; Fountain Valley, California; La Mesa, California · 111 sites in all
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07196722 · 1,092 participants (planned) · Start Oct 3, 2025 · Primary completion Sep 19, 2028
Drug: Icotrokinra; Placebo · For: Crohn Disease
Sites: Chandler, Arizona; Litchfield Park, Arizona; Scottsdale, Arizona · 395 sites in all
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07691970 · 1,072 participants (planned) · Start Aug 31, 2026 · Primary completion Dec 30, 2032
Drug: Anifrolumab · For: Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 166 sites in all
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184996 · 980 participants (planned) · Start Oct 8, 2025 · Primary completion May 9, 2028
Drug: Duvakitug; Placebo · For: Ulcerative Colitis
Sites: Peoria, Arizona; Scottsdale, Arizona; Tucson, Arizona · 240 sites in all
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184931 · 980 participants (planned) · Start Oct 1, 2025 · Primary completion May 14, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Peoria, Arizona; Scottsdale, Arizona; Tucson, Arizona · 461 sites in all
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07185009 · 751 participants (planned) · Start Jan 16, 2026 · Primary completion Sep 21, 2028
Drug: Duvakitug; Placebo · For: Ulcerative Colitis
Sites: Tucson, Arizona; Coronado, California; Murrieta, California · 171 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.